# Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

> **NCT01502917** · PHASE1 · COMPLETED · sponsor: **Y-mAbs Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- Brain Cancer
- Brain Stem Glioma

## Interventions

- **DRUG:** Radioactive iodine-labeled monoclonal antibody omburtamab
- **RADIATION:** External Beam Radiotherapy

## Key facts

- **NCT ID:** NCT01502917
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502917, "Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01502917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*